51.54USD+7.10%Mkt Cap: 6.19B USDP/E: —Last update: 2026-05-26
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap6.19B USD
Enterprise Value5.44B USD
Revenue (TTM)—
Gross Profit-211.58M USD
Net Income (TTM)-377.94M USD
Revenue/Share—
Last Price51.54 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees289
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS80706P1030
Valuation
P/E (Trailing)—
P/E (Forward)-19.84
PEG—
EV/EBITDA-13.34
EV/Revenue—
P/S—
P/B21.09
EPS (TTM)-3.45
EPS (Forward)-2.41
52W Range
27.0797% of range52.19
52W High52.19 USD
52W Low27.07 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-153.95%
ROA-93.49%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-300.04M USD
CapEx (TTM)602.00K USD
FCF Margin—
FCF Yield-2.78%
Net Debt-274.27M USD
Net Debt/EBITDA0.67
Balance Sheet
Debt/Equity0.44
Current Ratio8.64
Quick Ratio8.41
Book Value/Sh2.263 USD
Cash/Share4.005 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)59.00 USD
Target Range48.00 USD – 70.00 USD
# Analysts16
Ownership
Shares Out.119.83M
Float91.86M
Insiders0.76%
Institutions116.17%
Short Interest
Short Ratio9.2d
Short % Float15.68%
Short % Out.12.49%
Shares Short14.91M
Short (prev mo.)15.74M
Technical
SMA 5046.86 (+10.0%)
SMA 20040.82 (+26.3%)
Beta0.71
S&P 52W Chg28.31%
Avg Vol (30d)1.32M
Avg Vol (10d)1.24M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—